# A Phase III Transition Study of DRL Rituximab to Reference Medicinal Products

> **NCT04268771** · PHASE3 · COMPLETED · sponsor: **Dr. Reddy's Laboratories Limited** · enrollment: 140 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **BIOLOGICAL:** Experimental: Arm A: DRL_RI
- **BIOLOGICAL:** Arm B: Rituxan®/Mabthera®

## Key facts

- **NCT ID:** NCT04268771
- **Lead sponsor:** Dr. Reddy's Laboratories Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-08
- **Primary completion:** 2022-01-26
- **Final completion:** 2022-04-20
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2023-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04268771

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04268771, "A Phase III Transition Study of DRL Rituximab to Reference Medicinal Products". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04268771. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*